^99mTc-MIBI Dual-phase Imaging with Hybrid SPECT/CT for the Diagnosis of Rare Parathyroid Carcinoma (#53)

8:30 AM

zejun chen

Serum Chromogranin A in the Screening and Diagnosis of GEP-NENs (#54)

8:30 AM

Feng Wang

Role of Ga-68 DOTANOC PET/CT scan in chemotherapy response evaluation in patients with neuroblastoma (#55)

8:30 AM

Deepa Singh

Preliminary results on the prognostic value of MTV and TLG on Ga-68-DOTATATE PET/CT in patients with Neuro-endocrine Tumours (#56)

8:30 AM

Mariza M Vorster

Phase I/II open-label trial to evaluate the safety and preliminary efficacy of ¹⁷⁷Lu-OPS201, a radiolabeled somatostatin receptor antagonist, in patients with somatostatin receptor-positive, progressive gastroenteropancreatic neuroendocrine tumors (#57)

8:30 AM

Rod Hicks

[⁶⁴Cu]CuCl₂ PET imaging for the evaluation of anticancer activity of Dextran-Catechin conjugate as a novel treatment for neuroblastoma (#58)

8:30 AM

Arvind ParMar

PET-CT with ⁶⁸Ga-DOTA-peptides in non gastro-entero-pancreatic (nonGEP) neuroendocrine tumors (NET). Initial experience (#59)

8:30 AM

Daniel Valenzuela

Safety and efficacy of peptide receptor radionuclide therapy (PRRT) using Lu-177 DOTATATE and capecitabine as a radiosensitizer in metastatic neuroendocrine tumors (NETs) (#60)

8:30 AM

Ashwani Sood

¹⁷⁷Lu-DOTATATE peptide receptor chemo-radionuclide therapy (PRCRT) for SDHB-mutated metastatic paraganglioma: a case study (#61)

8:30 AM

Shamil D Cooray

Ga-68-DOTANOC PET/CT scan- role in clinical management with advantage over conventional imaging in patients of neuroendocrine tumors (#62)

8:30 AM

Deepa Singh

Unusual Neuroendocrine tumour cases (#63)

8:30 AM

Simon Gray

Efficacy of peptide receptor radionuclide therapy in neuroendocrine neoplasms: the Bad Berka experience in 1048 patients over more than a decade (#64)

8:30 AM

Harshad R Kulkarni

Efficacy and Safety of Peptide Receptor Radionuclide Therapy with/without Capcitabine in Asymptomatic Rectal Neuronedocrine Tumour: Malaysian Initial Experience (#65)

8:30 AM

TEIK HIN TAN

Comparison of the Functional Response and Tumour Sink Effect in Patients with High and Low Liver Dose on the Dosimetry Scan   (#66)

8:30 AM

Steven J Goodman

Patient dosimetry assessment with the somatostatin receptor antagonist ⁶⁸Ga-labelled OPS202 in the first clinical study of gastroenteropancreatic neuroendocrine tumors (GEP-NET) (#67)

8:30 AM

Uta Eberlein

Theranostics – RBWH experience (#68)

8:30 AM

Manoj Bhatt

A fully automated synthesis for the preparation of ^64,67Cu-SARTATE using the iPHASE MultiSyn Radiosynthesiser (#69)

8:30 AM

Charmaine Jeffery

Interactions of ¹⁷⁷lu-Dotatate With Pharmaceutical Vehicles And Peptides (#70)

8:30 AM

Makrem BEN REGUIGA

 [⁹⁰Y]DOTATOC manufacture of patient specific doses based on prior personal dosimetry. (#71)

8:30 AM

Gordon L Watkins

Dose-finding studies of ¹⁷⁷Lu-DOTA-peptides for PRRT. Studies on formulation by varying Specific Activity (SA) of ¹⁷⁷Lu-DOTA-peptides as a tool to optimize activity at contant amount of peptide (#103)

8:30 AM

Wouter AP Breeman

⁶⁸Ga-DOTATATE PET- CT in the evaluation of Congenital Hyperinsulinism (#125)

8:30 AM

Daniel Valenzuela

Feasibility of Insulinoma Radiotheranostics: [⁶⁸Ga]Ga-DO3A-VS-Cys⁴⁰-Exendin-4 and [¹⁷⁷Lu]Lu-DO3A-VS-Cys⁴⁰-Exendin-4 (#126)

8:30 AM

Irina Velikyan